Purinergic signalling in the nervous system: an overview - PubMed (original) (raw)
Review
Purinergic signalling in the nervous system: an overview
Maria P Abbracchio et al. Trends Neurosci. 2009 Jan.
Abstract
Purinergic receptors, represented by several families, are arguably the most abundant receptors in living organisms and appeared early in evolution. After slow acceptance, purinergic signalling in both peripheral and central nervous systems is a rapidly expanding field. Here, we emphasize purinergic co-transmission, mechanisms of release and breakdown of ATP, ion channel and G-protein-coupled-receptor subtypes for purines and pyrimidines, the role of purines and pyrimidines in neuron-glial communication and interactions of this system with other transmitter systems. We also highlight recent data involving purinergic signalling in pathological conditions, including pain, trauma, ischaemia, epilepsy, migraine, psychiatric disorders and drug addiction, which we expect will lead to the development of therapeutic strategies for these disorders with novel mechanisms of action.
Similar articles
- Purinergic signalling: past, present and future.
Burnstock G. Burnstock G. Braz J Med Biol Res. 2009 Jan;42(1):3-8. doi: 10.1590/s0100-879x2008005000037. Epub 2008 Oct 3. Braz J Med Biol Res. 2009. PMID: 18853040 Review. - The birth and postnatal development of purinergic signalling.
Burnstock G, Fredholm BB, North RA, Verkhratsky A. Burnstock G, et al. Acta Physiol (Oxf). 2010 Jun;199(2):93-147. doi: 10.1111/j.1748-1716.2010.02114.x. Epub 2010 Mar 24. Acta Physiol (Oxf). 2010. PMID: 20345419 Review. - Introductory overview of purinergic signalling.
Burnstock G. Burnstock G. Front Biosci (Elite Ed). 2011 Jun 1;3(3):896-900. doi: 10.2741/e298. Front Biosci (Elite Ed). 2011. PMID: 21622101 Review. - An introduction to the roles of purinergic signalling in neurodegeneration, neuroprotection and neuroregeneration.
Burnstock G. Burnstock G. Neuropharmacology. 2016 May;104:4-17. doi: 10.1016/j.neuropharm.2015.05.031. Epub 2015 Jun 6. Neuropharmacology. 2016. PMID: 26056033 Review. - Purinergic signalling: Its unpopular beginning, its acceptance and its exciting future.
Burnstock G. Burnstock G. Bioessays. 2012 Mar;34(3):218-25. doi: 10.1002/bies.201100130. Epub 2012 Jan 11. Bioessays. 2012. PMID: 22237698 Review.
Cited by
- Construction and validation of a comprehensive metabolism-associated prognostic model for predicting survival and immunotherapy benefits in ovarian cancer.
Ye W, Fang Y, Wei Z. Ye W, et al. J Cancer. 2024 Sep 23;15(18):5986-6001. doi: 10.7150/jca.100796. eCollection 2024. J Cancer. 2024. PMID: 39440060 Free PMC article. - Acyclic sesquiterpenes nerolidol and farnesol: mechanistic insights into their neuroprotective potential.
Singh A, Singh L. Singh A, et al. Pharmacol Rep. 2024 Oct 22. doi: 10.1007/s43440-024-00672-8. Online ahead of print. Pharmacol Rep. 2024. PMID: 39436564 Review. - Dysregulated Purinergic Signalling in Fragile X Syndrome Cortical Astrocytes.
Reynolds KE, Napier M, Fei F, Green K, Scott AL. Reynolds KE, et al. Neuromolecular Med. 2024 Sep 10;26(1):36. doi: 10.1007/s12017-024-08802-4. Neuromolecular Med. 2024. PMID: 39254908 - Extracellular purines in lung endothelial permeability and pulmonary diseases.
Gerasimovskaya E, Patil RS, Davies A, Maloney ME, Simon L, Mohamed B, Cherian-Shaw M, Verin AD. Gerasimovskaya E, et al. Front Physiol. 2024 Aug 20;15:1450673. doi: 10.3389/fphys.2024.1450673. eCollection 2024. Front Physiol. 2024. PMID: 39234309 Free PMC article. Review. - Activation of P2X7R Inhibits Proliferation and Promotes the Migration and Differentiation of Schwann Cells.
Su W, He X, Lin Z, Xu J, Shangguan J, Wei Z, Zhao Y, Xing L, Gu Y, Chen G. Su W, et al. Mol Neurobiol. 2024 Sep 3. doi: 10.1007/s12035-024-04460-6. Online ahead of print. Mol Neurobiol. 2024. PMID: 39225968
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources